INTRODUCTION
Salmonella enterica serotypes Typhi, Paratyphi A, Paratyphi B, and Paratyphi C are grouped as typhoidal Salmonella, and other serovars are described as non-typhoidal Salmonella (NTS). Typhoidal Salmonella are human host-restricted bacteria that cause typhoid fever, a systemic disease, and paratyphoid fever. Non-typhoidal Salmonella strains may be host-generalists, capable of infecting or colonizing a broad range of vertebrate animals species, or host-specialists, adapted or restricted to particular nonhuman animal species.1 Although most salmonellosis due to NTS results in self-limited acute gastroenteritis, NTS have emerged as an important cause of bloodstream infection.2 In 2010, they were estimated to have caused approximately 3.4 million invasive infections and 681,000 deaths worldwide. Europe (102 cases/100,000 population) and the Americas (23 cases/100,000 population) had the second and third most cases of invasive NTS, respectively, but the numbers were substantially lower than that for Africa (227 cases/100,000 population). Young children, the elderly, malaria-infected and malnourished children, and immunocompromised people are at particular risk for invasive disease, which explains at least partially the discrepancies in incidence among regions.3
Guadeloupe, a French overseas territory located in the Caribbean, is a very high-resource country according to the Human Development Index in 2013. Although few data are available on the epidemiology of Salmonella in humans in the Caribbean, it appears to be specific. In Martinique and Guadeloupe, S. enterica Panama was a major serovar, representing 35% of all isolates between 1990 and 1994 (first rank)4 and 15% between 1992 and 1995 (second rank).5 Surprisingly, this serovar has been rarely encountered in metropolitan France or in other regions of the world.6 At the University Hospital of Pointe-à-Pitre, around 35% (268/805) of the Salmonella isolates from humans belonged to serovars Panama and Arechavaleta during the period 2005–2014 (personal communication). The Panama serovar appears to have a propensity to cause bloodstream infection and severe human disease.4,5,7 We, therefore, conducted a retrospective study to identify the risk factors associated with NTS bacteremia in infants and children in Guadeloupe and to determine the pathogenicity of Salmonella serovars by analyzing their contribution to Salmonella bacteremia. Antimicrobial susceptibility was also evaluated.
MATERIAL AND METHODS
Population.
Between January 2010 and December 2014, 171 infants and children aged ≤ 15 years admitted to the emergency room at the University Hospital in Pointe-à-Pitre with Salmonella infection confirmed by stool and blood culture were included. A specific, standard anonymized medical questionnaire was completed to collect demographic, clinical, and biological data and information on associated pathologies. Empirical antibiotic therapy was considered appropriate if the treatment regimen included at least one antibiotic that was active in vitro against the infecting microorganisms. The study protocols were approved by the French Advisory Committee on Information Processing in Material Research in the Field of Health (CCTIRS 11–40).
Microbiological analysis and serotyping.
Strains were serotyped on the basis of somatic O and both phase 1 and phase 2 flagellar antigens by agglutination tests with antisera (Bio-Rad, Marnes-La-Coquette, France), as specified in the White–Kauffmann–Le Minor scheme.8 Antibiotic susceptibility to amoxicillin, amoxicillin–clavulanic acid, ticarcillin, cefalotin, cefoxitin, cefotaxime, ceftazidime, amikacin, tobramycin, gentamicin, nalidixic acid, ciprofloxacin, chloramphenicol, sulfonamides, cotrimoxazole, and tetracycline was determined by the disk diffusion method on Mueller–Hinton agar (Bio-Rad) according to the 2017 guidelines of the French Society for Microbiology/EUCAST (http://www.sfm-microbiologie.org). The minimum inhibitory concentrations (MICs) for ceftriaxone, ceftazidime and ciprofloxacin for strains resistant to these antibiotics were determined by the disk diffusion method on E-test strips (BioMerieux, Marcy L’Etoile, France). Salmonella strains that showed resistance to cefotaxime and/or ceftazidime were tested for the presence for extended-spectrum beta-lactamase (ESBL) by the double-disk synergy method.
If more than one isolate with the same serotype and antimicrobial resistance phenotype was recovered from the same patient, only the first was retained for the analysis.
Statistical analysis.
Children and infants were divided into those with bacteremia with or without gastroenteritis and those without bacteremia. Acute gastroenteritis was defined as diarrhea with a stool culture positive for Salmonella. Bacteremia was established when Salmonella was isolated from a blood culture.
Microsoft Access 2003 was used for data entry and Stata Version 10 for statistical analysis. In univariate analyses, the χ2 test (or Fisher’s exact test when appropriate) and Student’s t test were used to compare categorical and continuous variables, respectively. Factors with P values < 0.20 in the univariate analysis were retained for the multivariate analysis. We considered P values < 0.05 to be significant.
RESULTS
Patient characteristics.
A total of 171 patients with S. enterica infection were included retrospectively over the 36-month study period. The sex ratio (M/F) was 0.94, and the median age was 18.3 months (mean, 30.3 months; 25th percentile, 6.4 months; 75th percentile, 43.0 months). No specific medical history was reported, except for sickle cell anemia in three children (one SS homozygous, one AS heterozygote, and one S/β heterozygote) and a brain tumor in one. A total of 155 (90.6%) patients presented with acute gastroenteritis, of whom 42 (27.1%) had concomitant bacteremia, and 16 (9.4%) with primary bacteremia. Of the 171 cases, 151 (88.3%) were hospitalized: 56 (96.6%) with bacteremia and 95 (84.0%) without (P = 0.016).
The characteristics of the 171 patients are presented in Table 1. Five children were in septic shock, but no deaths were reported.
Risk factors for bacteremia in patients aged ≤ 15 years admitted to the emergency room of the University Hospital of Pointe-aÌ-Pitre
Bacteremia | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
No N = 113 | Yes N = 58 | |||||
n (%) | n (%) | P | Adjusted OR | 95% CI | P | |
Age > 6 months | 80 (70.8) | 50 (86.2) | 0.02 | 2.5 | 0.89–7.00 | 0.08 |
Male sex | 56 (49.6) | 27 (46.5) | 0.71 | – | – | – |
Delay between onset of symptoms and admission > 5 days | 22 (19.5) | 24 (41.4) | 0.002 | 3.0 | 1.3–7.1 | 0.01 |
Underlying disease | 2 (1.8) | 2 (3.4) | 0.88 | – | – | – |
Serotype | ||||||
Panama | 36 (23.0) | 31 (53.4) | < 0.001 | 12.9 | 4.2–29.5 | < 0.001 |
Arechavaleta | 11 (9.7) | 17 (29.3) | 0.001 | 11.2 | 4.2–39.6 | < 0.001 |
Fever (> 38°C) | 95 (84.1) | 43 (91.4) | 0.23 | – | – | – |
Digestive symptoms | ||||||
Abdominal pain | 70 (62.0) | 36 (62.1) | 0.98 | – | – | – |
Liquid stools | 91 (80.5) | 47 (81.0) | 1 | – | – | – |
Bloody stools | 31 (27.4) | 12 (20.7) | 0.34 | – | – | – |
Vomiting | 41 (36.3) | 40 (69.0) | 0.005 | 3.9 | 1.7–9.0 | 0.001 |
Articular symptoms | 0 | 1 (1.7) | 0.73 | – | – | – |
Neurologic symptoms* | 4 (3.5) | 5 (8.6) | 0.15 | – | – | – |
Respiratory symptoms | ||||||
Apnea | 0 | 1 (1.7) | 0.73 | – | – | – |
Increased respiratory rate† | 7 (6.2) | 12 (20.7) | 0.004 | 8.4 | 2.3–30.9 | 0.001 |
Respiratory distress‡ | 1 (0.9) | 5 (8.6) | 0.009 | – | – | – |
Dehydration | 20 (17.7) | 9 (15.5) | 0.72 | – | – | – |
Hyperneutrophilia§ | 28 (24.8) | 9 (15.5) | 0.16 | 0.55 | 0.2–2.1 | |
C-reactive protein > 50 mg/L | 44 (38.9) | 26 (44.8) | 0.46 | – | – | – |
Hypotonia (N = 2), weak reflexes (N = 2), perturbation of consciousness (N = 3), and febrile convulsions (N = 3).
Normal respiratory rate (breaths per minute): 1 day to 6 months, < 60; 6 months to 1 year, < 50; 1–5 years, < 40; > 5 years, < 30.
Respiratory distress was not included in the multivariate analysis, as this variable is used to define severe sepsis and septic shock.
Absolute normal neutrophil count: 1 day to 1 month, 6–26.109/L; 1 month to 8 years, 1.5–8.5.109/L; 8–12 years, 1.8–8.109/L; > 12 years, 1.8–7.5.109/L.
Serotypes, antibiotic susceptibility, and antibiotic treatment.
All 171 isolates were analyzed. Two subspecies were recovered: enterica (N = 161, 94.2%) and houtenae (N = 10, 5.8%). All but one (serovar Typhi) were NTS. The most common serotypes were Panama (N = 57, 33.3% of isolates) and Arechavaleta (N = 28, 16.4%). The other major serotypes were Enteritidis (N = 23, 13.5%), Typhimurium monophasic variant 4,[5],12:i:- (N = 15, 8.8%), and 43:z4,z32:-:- (houtenae subspecies) (N = 9, 5.3%). Among the Salmonella blood isolates (N = 58), all but one (serovar Typhi) were NTS, of which 48 (82.8%) were assigned to Panama (N = 31, 53.4%) or Arechavaleta (N = 17, 29.3%) (Table 2).
Distribution of Salmonella enterica subsp. enterica and houtenae serovars in 171 patients aged ≤ 15 years admitted to the emergency room of the University Hospital of Pointe-à-Pitre
Stools | Blood | Total* | ||||||
---|---|---|---|---|---|---|---|---|
Serovar | N | % | Serovar | N | % | Serovar | N | % |
Panama | 54 | 35.1 | Panama | 31 | 53.4 | Panama | 57 | 33.3 |
Enteritidis | 23 | 14.9 | Arechavaleta | 17 | 29.3 | Arechavaleta | 28 | 16.4 |
Arechavaleta | 18 | 11.7 | 4,5,12:i:- | 2 | 3.4 | Enteritidis | 23 | 13.5 |
4,5,12:i:- | 15 | 9.7 | Enteritidis | 2 | 3.4 | 4,5,12:i:- | 15 | 8.8 |
43:z4.z32:-:-† | 9 | 5.8 | Newport | 2 | 3.4 | 43:z4,z32:-† | 9 | 5.3 |
Newport | 7 | 4.5 | Typhi | 2 | 3.4 | Newport | 7 | 4.1 |
Infantis | 5 | 3.2 | Rubislaw | 1 | 1.7 | Rubislaw | 7 | 4.1 |
Rubislaw | 5 | 3.2 | Schwarzengrund | 1 | 1.7 | Infantis | 5 | 2.9 |
Typhimurium | 4 | 2.6 | Typhimurium | 4 | 2.3 | |||
4,12:i:- | 2 | 1.3 | Typhi | 3 | 1.8 | |||
43:z4,z23:-:-† | 1 | 0.6 | 4,12:i:- | 2 | 1.2 | |||
Agona | 1 | 0.6 | 43:z4,z23:-† | 1 | 0.6 | |||
Braenderup | 1 | 0.6 | Agona | 1 | 0.6 | |||
Havana | 1 | 0.6 | Braenderup | 1 | 0.6 | |||
Javiana | 1 | 0.6 | Havana | 1 | 0.6 | |||
Miami | 1 | 0.6 | Javiana | 1 | 0.6 | |||
Mississippi | 1 | 0.6 | Miami | 1 | 0.6 | |||
Montevideo | 1 | 0.6 | Mississippi | 1 | 0.6 | |||
Pomona | 1 | 0.6 | Montevideo | 1 | 0.6 | |||
Poona | 1 | 0.6 | Pomona | 1 | 0.6 | |||
Schwarzengrund | 1 | 0.6 | Poona | 1 | 0.6 | |||
Typhi | 1 | 0.6 | Schwarzengrund | 1 | 0.6 | |||
Total | 154 | 100 | Total | 58 | 100 | Total | 171 | 100 |
If more than one isolate with the same serovar and antimicrobial resistance phenotype was recovered from the same patient, only the first was retained.
S. enterica subsp. houtenae.
Overall, the 171 Salmonella isolates showed a low level of resistance to all antibiotics: amoxicillin (N = 15, 11.4%), amoxicillin–clavulanic acid (N = 1, 0.8%), ticarcillin (N = 15, 11.4%), cefalotin (N = 2, 1.5%), cefoxitin (0%), cefotaxime (N = 1, 0.8%), ceftazidime (N = 1, 0.8%), imipenem (0%), amikacin (0%), tobramycin (0%), gentamicin (0%), nalidixic acid (N = 3, 2.3%), ciprofloxacin (N = 2, 1.5%), and cotrimoxazole (N = 2, 1.5%). No increase in the prevalence of resistance to antibiotics was observed during the study period. The only serovar Typhi strain, isolated in 2014, was resistant to ciprofloxacin (MIC, 1.5 mg/L), and an isolate belonging to serovar Typhimurium (2010) was resistant to all beta-lactams (MIC ceftazidime, 32 mg/L, MIC ceftriaxone, > 256 mg/L) except cefoxitin and imipenem and was susceptible to other antibiotic families. The double-disk synergy test was positive, indicating production of an ESBL.
Only four patients were admitted to the emergency room with a probabilistic antibiotic (amoxicillin). Most patients received antibiotic treatment on admission (86.0%, 147/171), consisting mainly of third-generation cephalosporins (76.6%, 131/171). Other commonly prescribed antibiotics were amoxicillin (N = 8), amoxicillin–clavulanic (N = 7), and cotrimoxazole (N = 1). The treatment was adequate in all cases except one (third-generation cephalosporin for a strain resistant to this antibiotic). Antibiotic treatment was prescribed significantly more to patients with bacteremia than to those without (95.0% versus 81.4%, P < 0.016).
Risk factors for Salmonella bacteremia.
A delay between the onset of symptoms and hospital admission > 5 days (P = 0.002), age > 6 months (P = 0.002), infection with Panama or Arechavaleta serovar (P < 0.001), vomiting (P = 0.005), and increased respiratory rate (P = 0.004) were significantly associated with bacteremia in the univariate analysis. A delay between the onset of symptoms and hospital admission > 5 days, infection with Panama or Arechavaleta serovar, vomiting, and increased respiratory rate were the main independent contributors to bacteremia in the multivariate analysis (Table 1).
Univariate analysis showed that only age > 6 months was associated with infection with Panama or Arechavaleta serovar (P = 0.002).
DISCUSSION
The serovar most often recovered in our study was Panama, as found in Martinique (38.5% of all strains investigated) and French Guiana (11.7%).4,6 Panama was also the major serovar in humans in Colombia and Chile.9,10 This high prevalence is in contrast to that in other regions of the world, including mainland France (0.5% in 2011),11 highlighting the specific epidemiology of these regions. In industrialized countries, NTS is transmitted predominantly through commercially produced food contaminated with animal feces.1 The reservoir appears to be different for the Panama serovar, as suggested by the four recently described cases of Salmonella Panama meningitis in exclusively breastfed infants in French Guiana.12 In addition, no Salmonella Panama isolate was found among 275 Salmonella spp. isolated from 1,636 samples from bovine, porcine, and avian food products and from poultry and the poultry environment between 2010 and 2014 at the Food Testing Laboratory at the Institut Pasteur in Guadeloupe (unpublished data). Contact with animals, such as reptiles, is an important nonfood source of NTS infection.13,14 In Guadeloupe, wild reptiles and amphibians (e.g., lizards, geckos, and frogs) are commonly found in and around houses. Thus, a reptilian reservoir for the Panama serovar is plausible, as it is found in frogs, toads, turtles, lizards, and snakes,6,15,16 and the host range might be much larger because of its presence in wild birds, swine, poultry, and Indian mongooses.17–21 In our study, Arechavaleta was the second most important serovar. To the best of our knowledge, Arechavaleta has been identified only in cane toads, dogs, and Indian mongooses.21–23 The major serovar 43:z4,z32:- (houtenae subspecies) in our study is also exotic. It was recovered in one case of osteomyelitis in a Taylor’s cantil pit viper24 but never in humans. The other serovars have commonly been associated with human infections. Further investigations are needed to identify the reservoir of the exotic Panama, Arechavaleta, and 43:z4,z32:- Salmonella serovars in Guadeloupe, and a reptilian source of contamination should be investigated.
Although we had a small sample, we detected a tangible trend of association between age > 6 months and the Panama and Arechavaleta serovars in our study. Guadeloupe has a high rate of breastfeeding (around 90% in 2013),25 which protects neonates against infection through specific and nonspecific immune factors,26 and exclusive breastfeeding also avoids exposure to contaminated water or food.
Non-typhoidal Salmonella bacteremia usually occurs in 6–11% of children with gastroenteritis,7,27,28 which is less than the 27% observed in our study. Several factors are known to be associated with an increased risk for invasive disease among children with Salmonella infection, including HIV infection, sickle cell disease SS, and specific serovars of Salmonella. HIV status was not systematically investigated in our study, but none of the parents spontaneously declared their child to be seropositive, and we assumed that HIV infection was low in our population. Only four (2.3%) of the 171 patients with NTS bacteremia had underlying disease, three with sickle cell anemia, indicating that most of the cases of Salmonella bacteremia occurred in children with no underlying health condition.
Infection with Panama and Arechavaleta serovars was significantly associated with the occurrence of bacteremia. The Panama serovar was first isolated during an investigation of food poisoning among United States soldiers stationed in Panama in 1934,29 and this serovar has repeatedly been described as causing invasive disease, such as bacteremia and meningitis, in children.30–33 To the best of our knowledge, the Arechavaleta serovar has not been reported to cause severe infections. The way in which these two serovars cause invasive disease is unknown; however, both evolutionary theory and empirical comparisons predict that chronic pathogens such as Helicobacter pylori will become less virulent over time because of coevolution with their hosts.34 The disruption of coevolved hosts and Panama and Arechavaleta serovars might explain the severity of infection, as these serovars are probably poorly adapted to humans, as indicated by the fact that reptile-related salmonellosis has been associated with young age, a high rate of hospitalization, and invasive disease.35,36 The greater virulence of these serovars might also be an explanation. Further studies are needed to clarify their pathogenicity.
Patients whose clinical symptoms persisted for > 5 days and who had an increased respiratory rate on admission were significantly more likely to have bacteremia, in agreement with previous reports.37,38 The association between vomiting and bacteremia has not been described, but vomiting was found to be a predictive factor for NTS bacteremia in children aged < 5 years also infected with Plasmodium falciparum at a low parasite count.39 No deaths were reported in our study, indicating prompt, effective management. In contrast to the worldwide situation,40 the rates of resistance to all classes of antibiotics were low, and there was no increase in the prevalence of resistance to first-line antibiotics during the study period, which accounts for the high rate of adequate antibiotic treatment. One therapeutic failure due to the only ESBL-producing Salmonella isolate was observed. Although the rate of ESBL-producing Salmonella isolates in our study was low, consistent with studies elsewhere in the world (0–2.4%),8,41–43 it is important to continue monitoring antimicrobial susceptibility in Salmonella isolates from humans, as effective antimicrobial therapy reduces mortality and complications and shortens the illness.
In conclusion, the data reported here add to understanding of the epidemiology of Salmonella in the Caribbean. Non-typhoidal Salmonella bacteremia should be recognized in healthy infants and children of all ages. Panama and Arechavaleta were the two serovars most often recovered in our study, with a propensity to cause bloodstream infection. If NTS infection is suspected, blood should be cultured and antibiotics initiated in all infants and children ill enough to be admitted to hospital with clinical symptoms for > 5 days, vomiting, or an increased respiratory rate.
We thank the technicians of the microbiology laboratory at the University Hospital of Pointe-à-Pitre/Les Abymes (Guadeloupe).
REFERENCES
- 1.↑
Crump JA, Sjolund-Karlsson M, Gordon MA, Parry CM, 2015. Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive Salmonella infections. Clin Microbiol Rev 28: 901–937.
- 2.↑
Bornstein K, Hungerford L, Hartley D, Sorkin JD, Tapia MD, Sow SO, Onwuchekwa U, Simon R, Tennant SM, Levine MM, 2017. Modeling the potential for vaccination to diminish the burden of invasive non-typhoidal Salmonella disease in young children in Mali, west Africa. PLoS Negl Trop Dis 11: e0005283.
- 3.↑
Ao TT, Feasey NA, Gordon MA, Keddy KH, Angulo FJ, Crump JA, 2015. Global burden of invasive nontyphoidal Salmonella disease, 2010. Emerg Infect Dis 21: 941–949.
- 4.↑
Olive C, Mansuy JM, Desbois N, Roche B, Cecile W, Saint-Aime C, Jouannelle J, 1996. Salmonella Panama in Martinique: epidemiological and clinical aspects in hospitalised children. Med Mal Infect 26: 590–593.
- 5.↑
Adjide CC, Perez JM, Nicolas M, Renac R, Juminer B, 1998. Descriptive epidemiology of Salmonella isolated in the Pointe-a-Pitre/Abymes University Hospital, between 1992 and 1995. Med Mal Infect 28: 418–422.
- 6.↑
Gay N, Le Hello S, Weill FX, de Thoisy B, Berger F, 2014. Salmonella serotypes in reptiles and humans, French Guiana. Vet Microbiol 170: 167–171.
- 7.↑
Parry CM, Thomas S, Aspinall EJ, Cooke RP, Rogerson SJ, Harries AD, Beeching NJ, 2013. A retrospective study of secondary bacteraemia in hospitalised adults with community acquired non-typhoidal Salmonella gastroenteritis. BMC Infect Dis 13: 107.
- 8.↑
Arlet G, Barrett TJ, Butaye P, Cloeckaert A, Mulvey MR, White DG, 2006. Salmonella resistant to extended-spectrum cephalosporins: prevalence and epidemiology. Microbes Infect 8: 1945–1954.
- 9.↑
Rodriguez EC, Diaz-Guevara P, Moreno J, Bautista A, Montano L, Realpe ME, Della Gaspera A, Wiesner M, 2017. Laboratory surveillance of Salmonella enterica from human clinical cases in Colombia 2005–2011. Enferm Infecc Microbiol Clin 35: 417–425.
- 10.↑
Cordano AM, Virgilio R, 1996. Evolution of drug resistance in Salmonella Panama isolates in Chile. Antimicrob Agents Chemother 40: 336–341.
- 11.↑
Arslan H, Inci EK, Azap OK, Karakayali H, Torgay A, Haberal M, 2007. Etiologic agents of diarrhea in solid organ recipients. Transpl Infect Dis 9: 270–275.
- 12.↑
Elenga N 2017. Salmonella enterica serovar Panama meningitis in exclusive breastfeeding infants: report of 4 cases, clinical features and therapeutic challenges. Medicine (Baltimore) 96: e6665.
- 13.↑
Mermin J, Hoar B, Angulo FJ, 1997. Iguanas and Salmonella marina infection in children: a reflection of the increasing incidence of reptile-associated salmonellosis in the United States. Pediatrics 99: 399–402.
- 14.↑
Colomb Cotinat M, Jourdan da Silva N, Weill FX, Lailler R, Rosieres X, Le Hello S, 2014. Salmonelloses chez les jeunes enfants et exposition aux reptiles domestiques: investigation en France meìtropolitaine en 2012. Bull Epideìmiol Hebd. 1–2: 2–8.
- 15.↑
Nakadai A, Kuroki T, Kato Y, Suzuki R, Yamai S, Yaginuma C, Shiotani R, Yamanouchi A, Hayashidani H, 2005. Prevalence of Salmonella spp. in pet reptiles in Japan. J Vet Med Sci 67: 97–101.
- 16.↑
Ribas A, Poonlaphdecha S, 2017. Wild-caught and farm-reared amphibians are important reservoirs of Salmonella, a study in north-east Thailand. Zoonoses Public Health 64: 106–110.
- 17.↑
Kich JD, Coldebella A, Mores N, Nogueira MG, Cardoso M, Fratamico PM, Call JE, Fedorka-Cray P, Luchansky JB, 2011. Prevalence, distribution, and molecular characterization of Salmonella recovered from swine finishing herds and a slaughter facility in Santa Catarina, Brazil. Int J Food Microbiol 151: 307–313.
- 18.
Tamang MD, Gurung M, Nam HM, Moon DC, Kim SR, Jang GC, Jung DY, Jung SC, Park YH, Lim SK, 2015. Prevalence and characterization of Salmonella in pigs from conventional and organic farms and first report of S. serovar 1,4,[5],12:i:- from Korea. Vet Microbiol 178: 119–124.
- 19.
Matias CA, Pereira IA, de Araujo Mdos S, Santos AF, Lopes RP, Christakis S, Rodrigues Ddos P, Siciliano S, 2016. Characteristics of Salmonella spp. isolated from wild birds confiscated in illegal trade markets, Rio de Janeiro, Brazil. Biomed Res Int 2016: 3416864.
- 20.
Betancor L 2010. Prevalence of Salmonella enterica in poultry and eggs in Uruguay during an epidemic due to Salmonella enterica serovar Enteritidis. J Clin Microbiol 48: 2413–2423.
- 21.↑
Miller S, Amadi V, Stone D, Johnson R, Hariharan H, Zieger U, 2014. Prevalence and antimicrobial susceptibility of Salmonella spp. in small Indian mongooses (Herpestes auropunctatus) in Grenada, West Indies. Comp Immunol Microbiol Infect Dis 37: 205–210.
- 22.
Drake M, Amadi V, Zieger U, Johnson R, Hariharan H, 2013. Prevalence of Salmonella spp. in cane toads (Bufo marinus) from Grenada, West Indies, and their antimicrobial susceptibility. Zoonoses Public Health 60: 437–441.
- 23.↑
Seepersadsingh N, Adesiyun AA, Seebaransingh R, 2004. Prevalence and antimicrobial resistance of Salmonella spp. in non-diarrhoeic dogs in Trinidad. J Vet Med B Infect Dis Vet Public Health 51: 337–342.
- 24.↑
Clancy MM, Newton AL, Sykes JM, 2016. Management of osteomyelitis caused by Salmonella enterica subsp. Houtenae in a Taylor’s cantil (Agkistrodon bilineatus Taylori) using amikacin delivered via osmotic pump. J Zoo Wildl Med 47: 691–694.
- 25.↑
DREES, 2016. Deux Nouveau-Neìs Sur Trois Sont Allaiteìs aÌ la Naissance. Available at: http://drees.solidarites-sante.gouv.fr/IMG/pdf/er958.pdf/. Accessed February 11, 2018.
- 26.↑
Rowe SY, Rocourt JR, Shiferaw B, Kassenborg HD, Segler SD, Marcus R, Daily PJ, Hardnett FP, Slutsker L; Emerging Infections Program FoodNet Working Group, 2004. Breast-feeding decreases the risk of sporadic salmonellosis among infants in FoodNet sites. Clin Infect Dis 38 (Suppl 3): S262–S270.
- 27.↑
Vugia DJ, Samuel M, Farley MM, Marcus R, Shiferaw B, Shallow S, Smith K, Angulo FJ; Emerging Infections Program FoodNet Working Group, 2004. Invasive Salmonella infections in the United States, FoodNet, 1996–1999: incidence, serotype distribution, and outcome. Clin Infect Dis 38 (Suppl 3): S149–S156.
- 28.↑
Crump JA, Medalla FM, Joyce KW, Krueger AL, Hoekstra RM, Whichard JM, Barzilay EJ; Emerging Infections Program NWG, 2011. Antimicrobial resistance among invasive nontyphoidal Salmonella enterica isolates in the United States: national antimicrobial resistance monitoring system, 1996 to 2007. Antimicrob Agents Chemother 55: 1148–1154.
- 29.↑
Schiff F, 1938. Salmonella Panama, occurrence in serious infections of infants in New York city. JAMA 111: 2458–2460.
- 30.↑
Busetti M, Longo B, Colonna F, Dibello D, Barbi E, Campello C, 2002. Case report: Salmonella Panama osteomyelitis in a Ghanaian child with sickle cell disease. Pediatr Med Chir 24: 390–391.
- 31.
Choudhury SA, Berthaud V, Weitkamp JH, 2006. Meningitis caused by Salmonella Panama in infants. J Natl Med Assoc 98: 219–222.
- 32.
Geraci JE, Dearing WH, 1962. Salmonella Panama endocarditis cured with kanamycin therapy. Proc Staff Meet Mayo Clin 37: 552–560.
- 33.↑
Leeder FS, 1956. An epidemic of Salmonella Panama infections in infants. Ann N Y Acad Sci 66: 54–60.
- 34.↑
Kodaman N 2014. Human and Helicobacter pylori coevolution shapes the risk of gastric disease. Proc Natl Acad Sci USA 111: 1455–1460.
- 35.↑
Murphy D, Oshin F, 2015. Reptile-associated salmonellosis in children aged under 5 years in south west England. Arch Dis Child 100: 364–365.
- 36.↑
Meyer Sauteur PM, Relly C, Hug M, Wittenbrink MM, Berger C, 2013. Risk factors for invasive reptile-associated salmonellosis in children. Vector Borne Zoonotic Dis 13: 419–421.
- 37.↑
Aoki Y, Kitazawa K, Kobayashi H, Senda M, Arahata Y, Homma R, Watanabe Y, Honda A, 2017. Clinical features of children with nontyphoidal Salmonella bacteremia: a single institution survey in rural Japan. PLoS One 12: e0176990.
- 38.↑
Brent AJ, Oundo JO, Mwangi I, Ochola L, Lowe B, Berkley JA, 2006. Salmonella bacteremia in Kenyan children. Pediatr Infect Dis J 25: 230–236.
- 39.↑
Nielsen MV, Amemasor S, Agyekum A, Loag W, Marks F, Sarpong N, Dekker D, Adu-Sarkodie Y, May J, 2015. Clinical indicators for bacterial co-infection in Ghanaian children with P. falciparum infection. PLoS One 10: e0122139.
- 40.↑
MacFadden DR, Bogoch II, Andrews JR, 2016. Advances in diagnosis, treatment, and prevention of invasive Salmonella infections. Curr Opin Infect Dis 29: 453–458.
- 41.↑
Pardos de la Gandara M, Seral C, Castillo Garcia J, Rubio Calvo C, Weill FX, 2011. Prevalence and characterization of extended-spectrum beta-lactamases-producing Salmonella enterica isolates in Saragossa, Spain (2001–2008). Microb Drug Resist 17: 207–213.
- 42.
Monno R, Rizzo C, De Vito D, Nucleo E, Migliavacca R, Pagani L, Rizzo G, 2007. Prevalence, antimicrobial resistance, and extended-spectrum beta-lactamases characterization of Salmonella isolates in Apulia, southern Italy (2001–2005). Microb Drug Resist 13: 124–129.
- 43.↑
Egorova S, Kaftyreva L, Grimont PA, Weill FX, 2007. Prevalence and characterization of extended-spectrum cephalosporin-resistant nontyphoidal Salmonella isolates in adults in Saint Petersburg, Russia (2002–2005). Microb Drug Resist 13: 102–107.